ArticleDrug delivery and translational research2022
Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation.
Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Development and characterization of a topical ferrochelatase inhibitor nanoemulsion for choroidal neovascularization therapy.International journal of pharmaceutics: X · 2026Article
- Emulsion and Emulgel-Based Ophthalmic Drug Delivery Systems.Pharmaceutics · 2025Review
- Oleic acid Enriched Leciplexes as Novel Mucoadhesive Cationic Nanocarriers of Agomelatine for Glaucoma Treatment.AAPS PharmSciTech · 2025Article
- Ocular bio-lubricating materials: from lubrication mechanism to dry eye syndrome treatment.Regenerative biomaterials · 2025Review
- Self-Microemulsifying Drug Delivery System to Enhance Oral Bioavailability of Berberine Hydrochloride in Rats.Pharmaceutics · 2024Article
- The Effect of High-Pressure Homogenization Conditions on the Physicochemical Properties and Stability of Designed Fluconazole-Loaded Ocular Nanoemulsions.Pharmaceutics · 2023Article
- PLGA Nanoparticles Containing Natural Flavanones for Ocular Inflammation.Pharmaceutics · 2023Article
- A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation.Pharmaceutics · 2022Article
- Preparation andDrug delivery · 2022Article
- Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization:Drug delivery · 2022Article
- Development of Ciprofloxacin-Loaded Bilosomes In-Situ Gel for Ocular Delivery: Optimization, In-Vitro Characterization, Ex-Vivo Permeation, and Antimicrobial Study.Gels (Basel, Switzerland) · 2022Article
- Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation.Pharmaceutics · 2022Article
- Review
- Formulation and Evaluation of Moxifloxacin Loaded Bilosomes In-Situ Gel: Optimization to Antibacterial Evaluation.Gels (Basel, Switzerland) · 2022Article
- Formulation and Evaluation of Nano Lipid Carrier-Based Ocular Gel System: Optimization to Antibacterial Activity.Gels (Basel, Switzerland) · 2022Article
- Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics · 2021Review
- Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to develop and evaluate nanoemulsions (NEs) containing besifloxacin for ocular drug delivery. Pseudo ternary phase diagrams were constructed using Triacetin (oil), Cremophor
Indexed as
Identifiers
33575973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.